TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) CEO Robert Michael Dudley purchased 19,000 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The stock was acquired at an average price of $2.76 per share, with a total value of $52,440.00. Following the completion of the purchase, the chief executive officer […]